Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63–89.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA. 2015;314:80.

Article  PubMed  CAS  Google Scholar 

Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Down J. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol. 2004;172:1297–301.

Article  PubMed  Google Scholar 

Thompson IM. Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med. 2004;350:2239–46.

Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol. 2001;166:1679–83.

Article  PubMed  CAS  Google Scholar 

Wang Y, Wang X, Yu J, Ouyang J, Shen W, Zhou Y, et al. Application of transrectal ultrasound-guided repeat needle biopsy in the diagnosis of prostate cancer in Chinese population: a retrospective study. J Res Med Sci. 2016;21:79.

Article  PubMed  PubMed Central  Google Scholar 

Miyagawa T, Ishikawa S, Kimura T, Suetomi T, Tsutsumi M, Irie T, et al. Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol. 2010;16:850–60.

Google Scholar 

Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, Godehardt E, et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015;68:713–20.

Article  PubMed  Google Scholar 

Giganti F, Rosenkrantz AB, Villeirs G, Panebianco V, Stabile A, Emberton M, et al. The Evolution of MRI of the Prostate: The Past, the Present, and the Future. AJR Am J Roentgenol. 2019;213:384–96.

Article  PubMed  Google Scholar 

Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink M. Magnetic Resonance Imaging–targeted Biopsy May Enhance the Diagnostic Accuracy of Significant Prostate Cancer Detection Compared to Standard Transrectal Ultrasound-guided Biopsy: A Systematic Review and Meta-analysis. Eur Urol. 2015;68:438–50.

Article  PubMed  Google Scholar 

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. Magnetic resonance imaging-targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without prior biopsies: a randomized controlled trial. N Engl J Med. 2018;378:1767–77.

Article  PubMed  PubMed Central  Google Scholar 

Ghai S, Haider MA. Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol. 2015;31:194–201.

Article  PubMed  PubMed Central  Google Scholar 

Yu J, Fulcher AS, Winks SG, Turner MA, Clayton RD, Brooks M, et al. Diagnosis of typical and atypical transition zone prostate cancer and its mimics at multiparametric prostate MRI. Br J Radiol [20160693]. May 2017 [cited 2022 Aug 10];90.

Norris JM, Carmona Echeverria LM, Bott SRJ, Brown LC, Burns-Cox N, Dudderidge T, et al. What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? an analysis from the Promis cohort. Eur Urol. 2020;78:163–70.

Article  PubMed  PubMed Central  Google Scholar 

Privé BM, Israel B, Schilham MGM, Muselaers CHJ, Zamecnik P, Mulders PFA, et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer and Prostatic Dis. 2020;24:423–30.

Article  Google Scholar 

Li M, Huang Z, Yu H, Wang Y, Zhang Y, Song B. Comparison of PET/MRI with multiparametric MRI in diagnosis of primary prostate cancer: A meta-analysis. Eur J of Radiol. 2019;113:225–31.

Article  Google Scholar 

Grubmüller B, Baltzer P, Hartenbach S, Andrea DD, Helbich TH, Haug AR, et al. PSMA ligand PET/MRI for primary prostate cancer: Staging Performance and Clinical Impact. Clin Cancer Res. 2018;24:6300–7.

Article  PubMed  Google Scholar 

Taneja SS. Re: Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. J Urol. 2018;200:1165.

Article  Google Scholar 

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68GA-PSMA HBED-cc PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829–36.

Article  PubMed  CAS  Google Scholar 

Ferraro DA, Becker AS, Kranzbiihler B, Mebert I, Baltensperger A, Zeimpekis KG, et al. Diagnostic performance of 68GA-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: A prospective single-center study. Eur Nucl Med Mol Imaging. 2021;48:3315–24.

Article  Google Scholar 

Li Q, Xiang F, Lin X, Grajo JR, Yang L, Xu Y, et al. The role of Imaging in Prostate Cancer Care Pathway: Novel approaches to Urologic Management Challenges along 10 imaging touch points. Urology. 2018;119:23–31.

Article  PubMed  Google Scholar 

Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A, et al. Improving diagnosis of primary prostate cancer with combined GA-68 prostate-specific membrane antigen–HBED-cc simultaneous pet and multiparametric MRI and clinical parameters. AJR Am J Roentgenol. 2018;211:1246–53.

Article  PubMed  Google Scholar 

Jyoti R, Jain TP, Haxhimolla H, Liddell H, Barrett SE. Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with Prostate Cancer Gleason score. Eur J Radiol Open. 2018;5:58–63.

Sokmen BK, Sokmen D, Ucar N, Ozkurt H, Simsek A. The correlation between biological activity and diffusion-weighted MR imaging and ADC value in cases with prostate cancer. Arch Ital Urol Androl. 2017;89:277.

Article  PubMed  Google Scholar 

Ma T, Yang S, Jing H, Cong L, Chao Z, Liu Z, et al. Apparent diffusion coefficients in prostate cancer: Correlation with molecular markers Ki-67, HIF-1α and VEGF. NMR Biomed [29315957]. Jan 2018 [cited 2022 Aug 10];31.

Kubilay E, Akpinar C, Oguz ES, Araz MS, Soydal C, Baltaci S, et al. Significance of metabolic tumor volume and total lesion uptake measured using GA-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer. Urol Oncol-Semin Ori. 2022;40:408.e19-408.e25.

Article  CAS  Google Scholar 

Uslu-Beşli L, Bakir B, Asa S, Guner E, Demirdag C, Sahin OE, et al. Correlation of SUVmax and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. Mol Imaging Radionucl Ther. 2019;28:104–11.

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Yu F, Yang L, Zang S, Xue H, Yin X, et al. Ga-68 PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer. Medicine [e20755]. May 2020 [cited 2022 JUL 30];99.

Wetter A, Lipponer C, Nensa F, Heush P, Rubben H, Schlosser TW, et al. Quantitative evaluation of bone metastases from prostate cancer with simultaneous F-18 choline PET/MRI: combined SUV and ADC analysis. Ann Nucl Med. 2014;28:405–10.

Article  PubMed  CAS  Google Scholar 

Chinnappan S, Chandra P, Kumar JS, Chandran G, Nath S. SUVmax/ADC ratio as a molecular imaging biomarker for diagnosis of biopsy-naïve primary prostate cancer. Indian J Nucl Med. 2021;36:377–84.

Article  PubMed  PubMed Central  Google Scholar 

Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, et al. [68Ga]-PSMA versus [18F]PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature. Eur Urol Oncol. 2022;5:273–82.

Rodriguez De Dios N, Sanz X, Trampal C, Foro P, Reig A, Jimenez R, et al. 18F-FDG pet definition of gross tumor volume for radiotherapy of lung cancer: Is a single standardized uptake value threshold approach appropriate for lymph nodes and tumor delineation? International Journal of Radiation Oncology*Biology*Physics. 2009;75.

Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: The EANM Standardized Reporting Guidelines v1.0 for PSMA-PET. EJNMMI. 2021;48:1626–38.

Ingvar J, Hvittfeldt E, Trägårdh E, Simoulis A, Bjartell. Assessing the accuracy of F-18 PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Research. 2022;12.

Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-body 68ga-PSMA-11 pet/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guideline. J Nucl Med. 2019;61:405–11.

Article  PubMed  Google Scholar 

Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen pet: Clinical utility in prostate cancer, normal patterns, pearls, and Pitfalls. Radiographics. 2018;38:200–17.

Article  PubMed  Google Scholar 

Arnfield EG, Thomas PA, Roberts MJ, Pelecanos AM, Ramsay SC, Lin CY, et al. Clinical insignificance of [18F]-PSMA-1007 avid non-specific bone lesions: A retrospective evaluation. J Nucl Med. 2021;48:4495–507.

Article  CAS  Google Scholar 

Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: A Multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48:2239–48.

Article  Google Scholar 

Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa Christina A, Feuth T, Witjes JA, et al. Transition zone prostate cancer: Detection and localization with 3-T multiparametric mr imaging. Radiology. 2013;266:207–17.

Hoeks CM, Vos EK, Bomers JG, Barentsz JO, Hulsbergen-van de Kaa Christina A, Scheenen TW. Diffusion-weighted magnetic resonance imaging in the Prostate Transition Zone. Investigative Radiology. 2013;48:693–701.

Kim JH, Kim JK, Park B, Kim N, Cho KS. Apparent diffusion coefficient: Prostate cancer versus noncancerous tissue according to Anatomical Region. J Magn Reson Imaging. 2008;28:1173–9.

Article  PubMed  Google Scholar 

Barbosa F de, Queiroz MA, Nunes RF, Marin JFG, Buchpiguel CA, Cerri GG. Clinical perspectives of PSMA PET/MRI for prostate cancer. Clinics. 2018;73.

Bates A, Miles K. Prostate-specific membrane antigen pet/MRI validation of MR textural analysis for detection of transition zone prostate cancer. Eur Radiol. 2017;12(27):5290–8.

Article